Mandate

Vinge has advised the arranging banks in connection with Svenska Handelsbanken’s issue of Convertible Additional Tier 1 Capital in the amount of MUSD 500

February 19, 2019 Banking and Finance

Vinge has advised Morgan Stanley & Co. International plc and the other arranging banks consisting of Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Svenska Handelsbanken AB (publ) and UBS Limited in respect of Swedish law in connection with Svenska Handelsbanken’s issue of Additional Tier 1 bonds in the amount of approximately MUSD 500.

The bonds are perpetual instruments without a final maturity date, without the right of premature redemption during the first five years and with an automatic conversion to class A shares in the event that the bank’s core equity capital falls below a certain level. 

The issue will strengthen the bank’s core equity capital by 0.6 points. The issue will be subscribed and allocated to the arranging banks on 22 February 2019. 

The bonds will be listed on Euronext Dublin. 

Vinge’s team consisted of Mikael Ståhl, Josefine Larsson, Malte Hedlund and Paulina Malmberg.
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026